Anti-SARS-CoV-2 Monoclonal Antibody Distribution to High-risk Medicare Beneficiaries, 2020-2021.
retrospective_cohort · Level III
Where this comes from
- Record sourced from PubMed, PMID 35119452.
- Also identified by DOI 10.1001/jama.2022.1243 and PMC identifier 8904305.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
This study assesses how a limited supply of monoclonal antibody therapy was allocated to patients at highest risk of severe disease among a population of fee-for-service Medicare beneficiaries with a new COVID-19 diagnosis or confirmed exposure between November 2020 and August 2021.
Medical subject headings
- Antibodies, Monoclonal
- COVID-19 Drug Treatment